Elevated blood levels of neurofilament light chain (NfL), a biomarker of nerve cell damage, are linked to faster disease progression and shorter survival in most people with amyotrophic lateral sclerosis (ALS), a new study found. However, the team of researchers observed that blood NfL levels among patients differed by…
Men who are more active and physically fit have lower long-term risk of developing amyotrophic lateral sclerosis (ALS), according to findings from a large Norwegian study. No such link was observed in female patients, for reasons that are not entirely clear. The results may counter a concern that higher…
ALS patient Brian Wallach and his wife, Sandra Abrevaya, have made a significant and positive impact on the ALS community via their heart-wrenching 2022 documentary, “For Love & Life: No Ordinary Campaign.” In case you haven’t seen it yet, I won’t share much about the content. Suffice…
Biotechnology company ProJenX has received a $1 million grant from the ALS Association to support a portion of an ongoing clinical trial, which will test prosetin in people with amyotrophic lateral sclerosis (ALS). The PRO-101 Phase 1 trial (NCT05279755) is testing prosetin in three parts. The…
Since my husband, Todd, was diagnosed with ALS 14 years ago, I’ve been on the lookout for technology that will improve his comfort and quality of life while making my role as his caregiver safer and easier. Moving Todd is hard on me physically. He’s a big guy, and…
Amyotrophic lateral sclerosis (ALS) patients who used NeuroSense Therapeutics‘ investigational therapy PrimeC for a year saw significantly slower disease progression and prolonged survival relative to patients who started the treatment six months later. That’s according to one-year findings from the PARADIGM Phase 2b clinical trial (NCT05357950),…
I like collecting buzzwords. These are the popular words or phrases that weave their way into and out of our language every year. In fact, I think writing this weekly column for the past seven years has sharpened my sensitivity to trendy jargon. Some are fun to use and…
An advisory committee of the European Medicines Agency (EMA) has recommended against granting conditional marketing authorization to masitinib as an oral add-on treatment for amyotrophic lateral sclerosis (ALS). The negative opinion by the Committee for Medicinal Products for Human Use (CHMP) confirms the committee’s view, announced last…
Being diagnosed with ALS felt like a crushing blow to Craig. As a former band director who mentored students, he knew his life would change. Discover how Craig found his new purpose and community to inspire.
BrainStorm Cell Therapeutics has reached an alignment with the U.S. Food and Drug Administration (FDA) on the chemistry, manufacturing, and controls aspects — known as CMC — of the company’s upcoming Phase 3b trial of NurOwn (debamestrocel), to be tested in people with amyotrophic lateral sclerosis (ALS). This…
